Methotrexate-Conjugated Quantum Dots: Synthesis, Characterisation and Cytotoxicity in Drug Resistant Cancer Cells Publisher Pubmed



Johariahar M^{1, 2} ; Barar J^{1, 2} ; Alizadeh AM³ ; Davaran S^{1, 2} ; Omidi Y^{1, 2} ; Rashidi MR^{1, 2} Show Affiliations
Source: Journal of Drug Targeting Published:2016

Abstract

Methotrexate (MTX), a folic acid derivative, is a potent anticancer used for treatment of different malignancies, but possible initiation of drug resistance to MTX by cancer cells has limited its applications. Nanoconjugates (NCs) of MTX to quantum dots (QDs) may favour the cellular uptake via folate receptors (FRs)-mediated endocytosis that circumvents the efflux functions of cancer cells. We synthesised MTX-conjugated l-cysteine capped CdSe QDs (MTX-QD nanoconjugates) and evaluated their internalisation and cytotoxicity in the KB cells with/without resistancy to MTX. The NCs were fully characterised by high resolution transmission electron microscopy (HR-TEM), atomic force microscopy (AFM), dynamic light scattering (DLS) and optical spectroscopy. Upon conjugation with MTX, the photoluminescence (PL) properties of QDs altered, while an obvious quenching in PL of QDs was observed after physical mixing. The MTX-QD nanoconjugates efficiently internalised into the cancer cells, and induced markedly high cytotoxicity (IC50, 12.0 μg/mL) in the MTX-resistant KB cells as compared to the free MTX molecules (IC50,105.0 μg/mL), whereas, these values were respectively about 7.0 and 0.6 μg/mL in the MTX-sensitive KB cells. Based on these findings, the MTX-QD nanoconjugates are proposed for the targeted therapy of MTX-resistant cancers, which may provide an improved outcome in the relapsed FR-overexpressing cancers. © 2015 Informa UK Ltd. All rights reserved: reproduction in whole or part not permitted.